GSTCD: A Potential Drug Target and Biomarker (G79807)

Target Name: GSTCD

NCBI ID: G79807

GSTCD

Other Name(s): Glutathione S-transferase C-terminal domain-containing protein (isoform 1) | GSTCD variant 1 | Glutathione S-transferase C-terminal domain containing, transcript variant 1 | Glutathione S-transferase C-terminal domain-containing protein | GSTCD_HUMAN | glutathione S-transferase C-terminal domain containing | FLJ13273

GSTCD: A Potential Drug Target and Biomarker

Glutathione S-transferase C-terminal domain-containing protein (GSTCD) is a protein that plays a crucial role in the immune system and the production of antibodies. It is a key mediator in the regulation of cell growth, differentiation, and death. GSTCD has also been implicated in the development and progression of certain diseases. As a result, GSTCD has emerged as a promising drug target and biomarker.

GSTCD is a transmembrane protein that is expressed in most tissues and cells. It is composed of four distinct isoforms, Isoform 1 (GSTCD), Isoform 2, Isoform 3, and Isoform 4. These isoforms differ in their cytoplasmic localization and the presence or absence of certain genetic modifications. GSTCD is characterized by its ability to transfer glutathione across the cell membrane and to regulate the activity of several cellular signaling pathways, including the TGF-β pathway.

GSTCD functions as a negative regulator of the TGF-β pathway, which is a critical pathway involved in cell growth, differentiation, and survival. The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cell proliferation, cell survival, and the formation of tissues and organs. GSTCD is known to inhibit the activity of the TGF-β pathway by interacting with the protein Smad, which is a key regulator of the TGF-β pathway.

GSTCD has been shown to play a crucial role in the regulation of TGF-β signaling in various organisms, including humans. For example, GSTCD has been shown to inhibit the activity of the TGF-β pathway in cancer cells, which is thought to contribute to their uncontrolled growth and the development of certain diseases. Additionally, GSTCD has been shown to regulate the activity of the TGF-β pathway in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

GSTCD has also been shown to play a role in the regulation of cellular signaling pathways that are involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. GSTCD has been shown to interact with the protein N-cadherin, which is involved in the regulation of the neurotransmitter presynthesis pathway. This interaction between GSTCD and N-cadherin suggests that GSTCD may be involved in the regulation of neurotransmitter synthesis and the development of neurodegenerative diseases.

In addition to its role in the regulation of cellular signaling pathways, GSTCD has also been shown to play a role in the regulation of the immune system. GSTCD has been shown to interact with the protein PDGF-R2, which is involved in the regulation of cellular signaling pathways that are involved in cell growth, differentiation, and survival. This interaction between GSTCD and PDGF-R2 suggests that GSTCD may be involved in the regulation of immune cell function and the development of certain diseases.

GSTCD has also been shown to play a role in the regulation of cell death and the association with stress-induced cellular death. GSTCD has been shown to interact with the protein Bcl-2, which is involved in the regulation of cell death and the response to stress. This interaction between GSTCD and Bcl-2 suggests that GSTCD may be involved in the regulation of cell death and the association with stress-induced cellular death.

GSTCD has also been shown to play a role in the regulation of the efficacy of anticancer drugs. GSTCD has been shown to interact with the drug resistance protein P-gp, which is involved in the regulation of drug transport and efficacy. This interaction between GSTCD and P-gp suggests that GSTCD may be involved in the regulation of

Protein Name: Glutathione S-transferase C-terminal Domain Containing

The "GSTCD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSTCD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets